-
Metformin shown to increase a biological effect of exercise in men with prostate cancer reducing insulin resistance, easing metabolic stress and weight gain. What this isn’t is exercise in a pill.
Medical Mythbusting Commentary for April 14, 2026 Source:Exercise in a Pill? Metformin Shows Surprising Effects in Cancer Patients Reference:The anti-obesogenic metabolite, Lac-Phe, is elevated by metformin treatment in prostate cancer patients
-
Microplastics found in 90% of prostate cancer tumors, a study of ten men reveals. Much more data and larger population needed to determine if there is a causal relationship or reverse causality.
Medical Mythbusting Commentary for March 4, 2026 Source:Microplastics found in 90% of prostate cancer tumors, study reveals
-
Diabetes drug, Pioglitazone seems to inhibit the growth of certain types of prostate cancer. Further evaluation is needed due to the small study size but the science is sound.
Medical Mythbusting Commentary for May 27, 2025 Source:Diabetes Drug Stops Prostate Cancer From Coming Back Reference:The anti-diabetic PPARγ agonist Pioglitazone inhibits cell proliferation and induces metabolic reprogramming in prostate cancer
-
High resolution ultrasound could enable faster prostate cancer diagnosis
Medical Mythbusting Commentary for March 24, 2025 Source:High resolution ultrasound could enable faster prostate cancer diagnosis
-
Radioligand therapy for men with a specific type of prostate cancer can produce positive results but requires full disclosure of the side effects as well.
Medical Mythbusting Commentary for July 11, 2024 Source:Doctors excited about targeted prostate cancer therapy, but can’t prescribe it yet
-
Some physicians advocating renaming low-grade cancers as “not cancer”. I do not think this is the correct path to take. It seems a bit patronizing presume how patients will respond to the news of their diagnosis.
Medical Mythbusting Commentary for January 26, 2024 Source:The Cancer That Doctors Don’t Want to Call Cancer
-
Prostate cancer: New combination therapy could reduce progression risk
Medical Mythbusting Commentary for March 27, 2023 Source:Prostate cancer: New combination therapy could reduce progression risk Reference:TALAPRO-2 Supports First-Line Talazoparib/Enzalutamide in All-Comers With mCRPC
-
New insights into how prostate cancer protects itself from latest therapies after researchers uncover the gene responsible for this resistance while investigating new drug that circumvents these protective mechanisms.
Medical Mythbusting Commentary for November 28, 2022 Source:Drug triggers immune cells to attack prostate cancer Reference:Inhibiting ACK1-mediated phosphorylation of C-terminal Src kinase counteracts prostate cancer immune checkpoint blockade resistance.
-
McGill University study shows that a shortened course of radiation therapy is safe and effective for men with high-risk prostate cancer
Medical Mythbusting Commentary for October 24, 2022 Source:Shortened course of radiation therapy safe and effective for men with high-risk prostate cancer